ES2813629T3 - Compuestos de TAFA4 y usos de los mismos para tratar el dolor - Google Patents

Compuestos de TAFA4 y usos de los mismos para tratar el dolor Download PDF

Info

Publication number
ES2813629T3
ES2813629T3 ES14723045T ES14723045T ES2813629T3 ES 2813629 T3 ES2813629 T3 ES 2813629T3 ES 14723045 T ES14723045 T ES 14723045T ES 14723045 T ES14723045 T ES 14723045T ES 2813629 T3 ES2813629 T3 ES 2813629T3
Authority
ES
Spain
Prior art keywords
pain
tafa4
agonist
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14723045T
Other languages
English (en)
Spanish (es)
Inventor
Aziz Moqrich
Marie-Claire Delfini
Annabelle Mantilleri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix-Marseille Université
Centre National de la Recherche Scientifique
Original Assignee
Aix-Marseille Université
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix-Marseille Université, Centre National de la Recherche Scientifique filed Critical Aix-Marseille Université
Application granted granted Critical
Publication of ES2813629T3 publication Critical patent/ES2813629T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES14723045T 2013-05-06 2014-05-06 Compuestos de TAFA4 y usos de los mismos para tratar el dolor Active ES2813629T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305592.1A EP2801369A1 (en) 2013-05-06 2013-05-06 TAFA4 compounds and uses thereof for treating pain
PCT/EP2014/059247 WO2014180853A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Publications (1)

Publication Number Publication Date
ES2813629T3 true ES2813629T3 (es) 2021-03-24

Family

ID=48428409

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14723045T Active ES2813629T3 (es) 2013-05-06 2014-05-06 Compuestos de TAFA4 y usos de los mismos para tratar el dolor

Country Status (8)

Country Link
US (2) US9884088B2 (enExample)
EP (2) EP2801369A1 (enExample)
JP (1) JP6487419B2 (enExample)
CN (1) CN105209056B (enExample)
CA (2) CA2910652C (enExample)
DK (1) DK2994157T3 (enExample)
ES (1) ES2813629T3 (enExample)
WO (1) WO2014180853A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107430121B (zh) * 2015-03-13 2020-06-23 希森美康株式会社 受试物质的检测方法及在该方法中使用的试剂盒
CN111683592B (zh) * 2017-10-30 2023-11-03 加利福尼亚大学董事会 使用电化学传感器对分析物进行无校正的体内测量
KR102866162B1 (ko) * 2018-04-24 2025-10-01 주식회사 뉴라클사이언스 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
ES2943136T3 (es) * 2018-09-27 2023-06-09 Inst Nat Sante Rech Med Polipéptido de TAFA4 para su uso para reducir la inflamación cutánea
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
WO2021156310A1 (en) * 2020-02-04 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Tafa4 polypeptide or polynucleotide for treating inflammatory disease
JP7729824B2 (ja) * 2020-02-13 2025-08-26 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ マルガリン酸はｐｉｅｚｏ２媒介性疼痛を低減させる
TWI759788B (zh) * 2020-07-08 2022-04-01 台灣粒線體應用技術股份有限公司 萃取保護液用於自細胞分離粒線體並維持粒線體活性的用途
CA3239578A1 (en) 2021-12-17 2023-06-22 Stephane GAILLARD Peptides and methods for use in treating pain
MX2024007794A (es) * 2021-12-20 2024-07-02 Amgen Inc Peptidos de union a dll3 y usos de los mismos.
EP4499163A1 (en) * 2022-03-24 2025-02-05 Baxter International Inc. Dialysis system having thermoelectric heating
AR129441A1 (es) 2022-05-25 2024-08-28 Tafalgie Therapeutics Péptidos y métodos para el tratamiento del dolor
AU2023278710A1 (en) * 2022-05-31 2024-12-12 Elisigen Inc. Composition for treating retinal or macular diseases
CN120813839A (zh) 2023-02-17 2025-10-17 Naos生命科学研究所 一种用于筛选能够提高皮肤耐受阈值的生态生物型化合物的方法
WO2025116606A1 (ko) * 2023-11-30 2025-06-05 주식회사 뉴라클제네틱스 신규한 케모카인-유사 단백질 단편
WO2026119983A1 (en) 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases
CN121249875B (zh) * 2025-10-13 2026-03-20 上海交通大学医学院附属仁济医院 外周神经系统中的Mas相关G蛋白耦联受体D在缓解阿片类药物耐受中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090077680A1 (en) * 2000-06-12 2009-03-19 Alejandro Abuin Genetically Engineered and Photyped Mice and Stem Cell Clones for Producing the Same
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32

Also Published As

Publication number Publication date
JP2016519138A (ja) 2016-06-30
US9884088B2 (en) 2018-02-06
EP2994157A1 (en) 2016-03-16
EP2994157B1 (en) 2020-07-01
US20160113996A1 (en) 2016-04-28
CA2910652A1 (en) 2014-11-13
JP6487419B2 (ja) 2019-03-20
DK2994157T3 (da) 2020-08-24
CA3235916A1 (en) 2014-11-13
US20180110829A1 (en) 2018-04-26
CA2910652C (en) 2024-05-28
EP2801369A1 (en) 2014-11-12
CN105209056A (zh) 2015-12-30
WO2014180853A1 (en) 2014-11-13
CN105209056B (zh) 2018-01-23

Similar Documents

Publication Publication Date Title
US9884088B2 (en) TAFA4 compounds and uses thereof for treating pain
Bączyk et al. Synaptic restoration by cAMP/PKA drives activity-dependent neuroprotection to motoneurons in ALS
Weir et al. Using an engineered glutamate-gated chloride channel to silence sensory neurons and treat neuropathic pain at the source
JP2021118745A (ja) Ｃ９ｏｒｆ７２遺伝子座における破壊を有する非ヒト動物
ES2886855T3 (es) Composiciones farmacéuticas para tratar el dolor
Basu et al. Ventromedial hypothalamic nucleus subset stimulates tissue thermogenesis via preoptic area outputs
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
EP3704271A1 (en) Neurokinin antagonists and uses thereof
Mayer et al. Kappa opioid receptor antagonism rescues genetic perturbation of dopamine homeostasis: Molecular, physiological and behavioral consequences
Iwasaki et al. A novel analgesic pathway from parvocellular oxytocin neurons to the periaqueductal gray
ES3036928T3 (en) Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
Class et al. Patent application title: TAFA4 COMPOUNDS AND USES THEREOF FOR TREATING PAIN Inventors: Aziz Moqrich (Marseille, FR) Marie-Claire Delfini (Marseille, FR) Annabelle Mantilleri (Apt, FR)
WO2019126894A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables, en el tratamiento de epilepsia refractaria
Mousseau Microglial Panx1 is a Spinal Determinant of Arthritis Joint Pain
Fuller An investigation into noxious mechanosensation, and the role of peripheral neuron subpopulations in pain
Lin Cell Type-Specific FGF13 Regulation of Neuronal Function
Tolou Dabbaghian Use of pharmaceutical and transgenic interventions in dissection of neuropathic pain mechanisms in spinal cord injury
De Rocco Pharmacological modulation of neuronal activity for the treatment of Rett syndrome
Ilaria et al. Voltage-independent GluN2A-type NMDA receptor Ca2+ signaling promotes audiogenic seizures, attentional and cognitive deficits in mice
Hu Chemogenetic inhibition of sensory neuron excitability attenuates pain-like behaviours
Astrocyte-Mediated ASNTR 2023 Abstracts
Gandhi Organisation of Glutamatergic Inputs to Central Amygdala
Omer Characterizing Rare Disease-Causing Mutations in Genes Affecting Cation-Coupled Chloride Cotransport
Kosse Functional properties of GAD65 neurons in the lateral hypothalamus
Wang A spinal circuit for thermal pain regulated by ErbB4